Amazon to spin up a secretive lab focused on cancer research
Category: #health  By Shikha Sinha  Date: 2018-06-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Amazon to spin up a secretive lab focused on cancer research

Following its entry into the healthcare realm, the e-commerce behemoth Amazon has been recently found leading a secretive research group called Grand Challenge. The group, led by the creator of Google Glass is reportedly working on medical records, cancer research, and last-mile delivery that could eventually expand the tech giant’s footprint beyond e-commerce, hardware, and Amazon Web Services.

Sources familiar with the matter reveal that one of the important initiatives Amazon will be focusing on is applying machine learning to cancer research. The company will partner with Fred Hutchinson Cancer Research Center, which is located close to Amazon’s headquarters in Seattle.

A Fred Hutch spokesperson was reported saying that the research centers have several projects underway with industry magnates including Tableau, Microsoft, and Amazon. He further added that they don’t have any specific Amazon Web Services projects to preview currently but hopefully may have some later this year. 

According to reliable reports, the secretive Amazon group, also called Amazon X and 1492, is pitching a health venture named as Hera to the health insurance companies. For the record, Grand Challenge is a part of Amazon Web Services and has been developing Hera for three years. The conjoint work is said to use e-records and identify a patient’s possible misdiagnosis. The reports further claim that the technology could do in-depth analysis and might help an insurance company remove inaccurate data to better assess risk.

For the uninitiated, Grand Challenge is run by the creator of Google Glass and former Google employee Babak Parviz, and is designed similar to the original Google X moonshots lab, a subsidiary of Alphabet which was known as X.

In other news, it has been reported that Amazon, Berkshire Hathaway, and JP Morgan Chase & Co. had announced plans in January to form an independent healthcare company that will focus initially on emerging technologies that will serve their US-based employees.



About Author

Shikha Sinha

Email: [email protected]   

Shikha Sinha

Shikha currently manages content operations for a series of news and business portals including MSF, Algosonline, and the like. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market resea...

Read More

More News By Shikha Sinha

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
By Shikha Sinha

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product cand...

NeurologyLive expands SAP program by partnering with Cleveland Clinic
NeurologyLive expands SAP program by partnering with Cleveland Clinic
By Shikha Sinha

NeurologyLive has reportedly added the Cleveland Clinic to its Strategic Alliance Partnership (SAP) program. Michael J. Hennessy Jr., President of NeurologyLive’s parent company MJH Associates Inc., said in a sta...

Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
By Shikha Sinha

Neurocrine Biosciences Inc., along with Voyager Therapeutics Inc., has reportedly announced the Phase 1 results from the VY-AADC trial in eight patients suffering from Parkinson’s disease. Apparently, the patient...